A process for the production of a-human atrial natriuretic polypeptide (a-hANP) involves firstly culturing a microorganism which has been transformed with an expression vector comprising a synthetic gene encoding the amino acid sequence of a protective peptide-fused a-hANP in a culture medium.
Subsequently recovering the protective peptide-fused a-hANP from the culture broth and then removing the protective peptide part from the peptide-fused polypeptide.
In addition to the process itself, chemically synthesised genes for a-hANP and protective peptide-fused a-hANP are also described together with the corresponding recombinant vectors and transformants comprising the same.
a-hANP is known to be useful as an antihypertensive diuretic agent.
生产人心房利
钠多肽(a-hANP)的工艺包括首先在
培养基中培养用表达载体转化的微
生物,表达载体包含编码保护性肽融合 a-hANP
氨基酸序列的合成
基因。
然后从培养液中回收保护性肽融合 a-hANP,再从肽融合
多肽中去除保护性肽部分。
除工艺本身外,还介绍了
化学合成的 a-hANP 和保护性肽融合 a-hANP
基因,以及相应的
重组载体和包含这些
基因的转化体。
已知 a-hANP 可用作降压利尿剂。